Home

<aside>

Rilemo's technology is the only portable, real-time electromagnetic brain imaging solution capable of operating in any point-of-care setting.

</aside>

To frame this positioning clearly, competitors can be divided into three categories:

• companies working on electromagnetic brain imaging devices directly comparable to Rilemo
• companies developing portable neuroimaging solutions using alternative technologies
• traditional diagnostic modalities that define the current standard of care.

Competitors in electromagnetic imaging

The electromagnetic imaging landscape for brain applications consists of a small number of companies developing non-invasive microwave-based solutions. However, no existing company currently offers a device that combines true portability, real-time imaging, and bedside usability in a single system.

** Research laboratories are not included in this table, a longer analysis is available on request*

EMVision (ASX: EMV) is the most advanced electromagnetic competitor, currently conducting pivotal clinical trials. Its bedside emu™ device is not yet commercially available and has not received CE marking or FDA clearance. Guidance pricing is approximately US$175,000 per unit.

Further information on Rilemo's technical advantages over these competitors is available in the Technology Overview section.

Portable neuroimaging - adjacent technologies

Beyond electromagnetic imaging, a growing category of portable brain imaging devices using alternative technologies is emerging. These solutions address the same clinical need, bedside neuroimaging without CT or MRI infrastructure, but through fundamentally different technological approaches with distinct trade-offs.

Hyperfine Swoop® (Nasdaq: HYPR) is the most commercially advanced player in this category. The Swoop system is an ultra-low-field portable MRI (0.064T) that is FDA cleared, CE marked, and commercially available across the United States and select European markets including Germany, France, and the United Kingdom. It sold 38 commercial systems in 2025 at an average selling price of approximately $360,000 per unit, generating revenue of ~$13.5M for the full year.

The commercial traction of Hyperfine validates the market for portable bedside neuroimaging. At the same time, the MRI technology approach entails structural constraints that Rilemo does not share:

Rilemo's significantly lower price point, true portability, and pre-hospital capability position it as a complementary and in many settings more accessible solution, particularly in ambulance, emergency, and resource-constrained environments where MRI infrastructure is not available.